Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study
| Autor: | J. Barrat, Gillet Jy, M.A. Domin, Philippe E, G. Magnin, M.A. Bruhat, André G, R. Erny, Faguer B, J.M. Kuhn, J.J. Leng, P. Lopes, M. Buvat-Herbaut, B. Hedon, E. Drapier-Faure |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Urology Administration Oral Endometrium Bedtime General Biochemistry Genetics and Molecular Biology Oral administration medicine Humans Amenorrhea Progesterone Aged Gynecology Estradiol medicine.diagnostic_test business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Hormone replacement therapy (menopause) Middle Aged Hyperplasia medicine.disease Menopause medicine.anatomical_structure Patient Compliance Female medicine.symptom business Endometrial biopsy |
| Zdroj: | Maturitas. 19:103-115 |
| ISSN: | 0378-5122 |
| DOI: | 10.1016/0378-5122(94)90060-4 |
| Popis: | The effects of oral micronized progesterone on the endometrium and bleeding pattern have been assessed in a multicenter study of 101 postmenopausal patients. During a minimum of 6 cycles, the participants received either percutaneous 17 beta-estradiol (1.5 mg/day) associated with micronized progesterone (100 mg/day), given at bedtime for 21/28 days or 25 days/calendar month (n = 98) [1], or E2 (3 mg/day) for 25 days associated with progesterone (300 mg/day), from day 16 to day 25 (n = 3) [2], according to their willingness to induce, or not, cyclic withdrawal bleeding. Each endometrial biopsy performed at 6-month minimum was assessed by two independent pathologists: results showed 61% quiescent without mitosis, 23% mildly active with very rare mitoses and 8% partial secretory endometrium. The remaining biopsies showed inadequate tissue (4%) or a sub-atrophy (4%). No hyperplasia was found by any pathologist. In the case of inadequate material, the mean thickness of endometrial mucosa measured by ultrasonography was 3.9 mm. Amenorrhea incidence was 93.3 and 91.6% at the 3rd and 6th month of therapy, respectively. No bleeding occurred in more than 80% of women. The results show that a low dose of oral progesterone (100 mg/day), given during 25 days, efficiently protects the endometrium by fully inhibiting mitoses and induces amenorrhea in the majority of postmenopausal women, allowing better compliance to long-term therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|